The USPTO is focused on ensuring our patent system incentivizes and protects the investments essential for bringing life-saving and life-altering drugs and biologics to market. At the same time, the USPTO is focused on ensuring our system, as a whole, is not used to improperly delay getting more affordable generic drugs and biosimilars into the hands of Americans who need them.
USPTO-FDA Collaboration Initiatives
The USPTO’s initiatives aim to enhance collaboration with other agencies; ensure that the USPTO issues robust and reliable patents; improve the process for post-grant challenges of issued patents; and improve public participation in the patent system.
Notices, blogs, and reports
Find our reports, Federal Register Notices (FRNs), USPTO leadership speeches and blogs, and other important information concerning drug and biologic patent policy.
Find information about USPTO engagement with other agencies and the public.
How to provide input
The USPTO welcomes public input on these and other initiatives the agencies should consider. We will soon post more information regarding upcoming public listening sessions on drug pricing initiatives to this page. In the meantime, please submit general inquiries to USPTO-FDAcollaboration@uspto.gov.